OLIGONUCLEOTIDES: TECHNOLOGY, STRATEGY, COLLABORATION – THE ESSENTIAL FUNDAMENTALS FOR SUCCESS
Oligonucleotides can be designed to control gene expression, essentially interfering with a disease’s ability to transmit, which makes them increasingly effective in controlling many illnesses. However, despite recent technological advances, efficient delivery of oligonucleotides remains a key challenge.
This exclusive event features oligonucleotide experts who have agreed to share their unique and personal experiences, insight, and advice to help companies understand and implement proper technology strategies needed to accelerate development; production and manufacturing strategies to support scale-up and sustainability; and collaboration strategies necessary to ensure long-term success.
OLIGONUCLEOTIDES – A CONVERSATION WITH DAVID COREY
David Corey, Rusty Kelley Professor of Medical Sciences, Department of Pharmacology and Biochemistry UT Southwestern Medical Center and President, Oligonucleotide Therapeutics Society shares his experiences and provides his advice on technology strategies to accelerate oligonucleotide R&D, including: (1) Selecting better targets based on disease indication and competitive advantages; (2) Evaluating the effectiveness of today’s “bread and butter” technologies; (3) Tweaking existing technologies to improve deliverability; (4) Leveraging technology to develop transparent, quality data to differentiate yourself; (5) Evaluating the impact of implementing new technologies
OLIGONUCLEOTIDES – A CONVERSATION WITH CHRIS OSWALD
Chris Oswald, Founder, Coswald Consulting LLC, Former Plant Manager, Agilent Technologies NASD, Boulder CO, shares his experiences and provides his advice on production and manufacturing strategies to support scale-up and sustainability, including: (1) Academia and Industry: Finding common ground and equipment to accelerate scale-up; (2) Implementing a CMC Strategy: Timing, budget, partners – what’s your priority?; (3) The Pinch Point: managing production volume with competition for ACN supply; (4) Evaluating currently available vs. up and coming approaches to scale; (5) Accepting Reality: Oligo production/scaleup is not easy and takes time
OLIGONUCLEOTIDES – A CONVERSATION WITH MIKE WEBB
Mike Webb, CEO and Principal, Mike Webb Pharma, Former Vice President, API Chemistry and Analysis, GSK, shares his experiences and provides his advice on creating proper collaboration strategies to ensure long-term success, including: (1) Selecting the right partner to properly connect science and funding; (2) Agreeing on a development approach — it’s all about front-loading and who does the heavy lifting; (3) Current manufacturing and analysis challenges; (4) Proper supply-side materials forecasting to support clinical trials; (5) The growing role of CDMO partners to support bulk manufacturing, Big Pharma or small biotech — choosing the partner